Mithra Reports 2017 Annual Results

 

Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on Women’s Health, today announces its results for the year ended 31 December 2017, prepared in accordance with IFRS.

Read the full press release and results here.

Note

Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in women's health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead development candidates - a fifth generation oral contraceptive, Estelle®, and a next generation hormone therapy, Donesta®- are built on Mithra's unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its Mithra CDMO. Mithra was founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

 

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?